| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101574 | LUPIN | Pharmaceutical composition containing fenofibrate and the preparation method |
Aug, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7863331 | LUPIN | Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
Aug, 2020
(3 years ago) | |
| US8026281 | LUPIN | Treating metabolic syndrome with fenofibrate |
Apr, 2025
(1 year, 1 day from now) | |
| US9314447 | LUPIN | Reduced dose pharmaceutical compositions of fenofibrate |
May, 2033
(9 years from now) | |
Antara (Micronized) is owned by Lupin.
Antara (Micronized) contains Fenofibrate.
Antara (Micronized) has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Antara (Micronized) are:
- US7863331
- US7101574
Antara (Micronized) was authorised for market use on 18 October, 2013.
Antara (Micronized) is available in capsule;oral dosage forms.
Antara (Micronized) can be used as treating severe hypertriglyceridemia, treating hypercholesterolemias with reduction of food effect.
The generics of Antara (Micronized) are possible to be released after 31 May, 2033.
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 18 October, 2013
Treatment: Treating hypercholesterolemias with reduction of food effect; Treating severe hypertriglyceridemia
Dosage: CAPSULE;ORAL
ANTARA (MICRONIZED) family patents
